相关实验视频

Updated: Jun 29, 2025

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

乳腺癌治疗的抗孕药:我们几乎准备好了

Andrés Elia¹, Gabriela Pataccini¹, Leo Saldain¹

¹Laboratory of Hormonal Carcinogenesis, Instituto de Biología y Medicina Experimental (IBYME CONICET), Buenos Aires, Argentina.

The Journal of steroid biochemistry and molecular biology

|March 30, 2024

概括

抗孕药在乳腺癌预防和治疗方面表现有前途,特别是在BRCA1突变载体中. 研究正在探索预测标记物,如PR异型比率和组合疗法,以确定响应的患者.

科学领域:

在瘤学瘤学.
内分泌学在内分泌学.
药理学药理学是一个学科.

背景情况:

抗孕药,最初用于妇科,在米费普里斯的发展后迅速被探索用于乳腺癌治疗.
针对包括乳腺癌在内的各种病理,正在研究具有副作用减少的新型抗孕药.
最近的研究涵盖了临床前模型和患者研究,重点是乳腺癌中的抗孕激素应用.

研究的目的:

对乳腺癌中抗孕激素的最新研究进行审查,从临床前研究到临床试验.
突出抗孕激素在预防乳腺癌方面的潜力,特别是对于BRCA1突变载体.
讨论预测患者对抗孕激素及其组合疗法的反应.

主要方法:

对乳腺癌中抗孕激素的临床前生物学模型和临床研究的审查.
调查PR异形比率作为抗孕激素反应的预测标记.
分析来自光线乳腺癌模型和患者样本的转录和蛋白质组数据.

主要成果:

抗孕药在BRCA1突变载体和特定患者群体的治疗中显示出预防乳腺癌的潜力.
PR异型比率正在成为预测抗孕激素治疗反应的工具.
在临床前模型中,正在探索使用塔莫西芬,CDK4/CDK6抑制剂或pembrolizumab的联合治疗.
转录基因和蛋白质基因分析显示,响应性乳腺癌模型中的增殖途径下降.

结论:

抗孕药是一种有前途的乳腺癌治疗途径,目前正在进行的研究重点是患者选择和组合策略.
了解PR异形比和分子通路对于优化抗孕激素疗效至关重要.
需要进一步的研究,以充分阐明抗孕激素在乳腺癌管理中的作用机制和临床效用.

关键词:

抗孕激素是一种抗孕激素.预防乳腺癌的预防方法乳腺癌治疗方法乳腺癌治疗方法临床试验中的临床试验.这就是Mifepristone.临床前研究临床前研究

更多相关视频

A Portal Vein Injection Model to Study Liver Metastasis of Breast Cancer

A Portal Vein Injection Model to Study Liver Metastasis of Breast Cancer

Published on: December 26, 2016

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...